| Stay updated on the top DIGITAL HEALTH NEWS |
|---|
|
|
15 - 18 November 2021, Düsseldorf, Germany.
Abbott (NYSE: ABT) has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software. This innovative imaging software combines OCT with artificial intelligence (AI) to provide physicians an enhanced, comprehensive view of coronary blood flow and blockages to assist physician decision-making and provide the best pathway for treatment.
The International Coalition of Medicines Regulatory Authorities (ICMRA) sets out recommendations to help regulators to address the challenges that the use of artificial intelligence (AI) poses for global medicines regulation, in a report published today.
AI includes various technologies (such as statistical models, diverse algorithms and self-modifying systems) that are increasingly being applied across all stages of a medicine's lifecycle: from preclinical development, to clinical trial data recording and analysis, to pharmacovigilance and clinical use optimisation.
Siemens Healthineers presents its second pathway for its AI-Pathway Companion(1) at the Healthcare Information and Management Systems Society Global Health Conference 2021 (HIMSS 21). This new pathway is focused on non-small cell lung cancer, supporting personalized and standardized decision-making along the whole treatment process(2).
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced the introduction of two new Philips HealthSuite solutions that are secure, cloud-based and intended to break down barriers across patient care in a scalable, cost-effective model.
By examining MRI data from a large Open Science repository, researchers reconstructed a brain connectivity pattern, and applied it to an artificial neural network (ANN). An ANN is a computing system consisting of multiple input and output units, much like the biological brain.
15 - 18 November 2021, Düsseldorf, Germany.There is an urgent need for more effective treatments for many conditions, including COVID-19, cancer and malaria. But the process of developing new drugs is costly, can take decades, and often leads to failed treatments.